secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-05-14T12:05:14+00:00
Accession:  0001437749-26-016883
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model
-------------------------------------------------------------------------------

- Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.
- Treatment improved β-cell function: increased insulin granules, improved glucose-stimulated insulin secretion vs controls.
- β-cell-specific targeting (RIP-PM-GFP) also reversed hyperglycemia, indicating enhanced β-cell maturation.
- Approach is translatable to humans via endoscopic retrograde cholangiopancreatography delivery to the pancreas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/0001437749-26-016883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/gnpx20260513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-016883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer